全文获取类型
收费全文 | 1230篇 |
免费 | 83篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 32篇 |
妇产科学 | 27篇 |
基础医学 | 163篇 |
口腔科学 | 14篇 |
临床医学 | 102篇 |
内科学 | 364篇 |
皮肤病学 | 5篇 |
神经病学 | 280篇 |
特种医学 | 29篇 |
外科学 | 132篇 |
综合类 | 5篇 |
一般理论 | 1篇 |
预防医学 | 33篇 |
眼科学 | 8篇 |
药学 | 72篇 |
中国医学 | 5篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 6篇 |
2022年 | 25篇 |
2021年 | 25篇 |
2020年 | 17篇 |
2019年 | 34篇 |
2018年 | 39篇 |
2017年 | 22篇 |
2016年 | 46篇 |
2015年 | 36篇 |
2014年 | 46篇 |
2013年 | 59篇 |
2012年 | 121篇 |
2011年 | 100篇 |
2010年 | 63篇 |
2009年 | 57篇 |
2008年 | 88篇 |
2007年 | 78篇 |
2006年 | 72篇 |
2005年 | 88篇 |
2004年 | 65篇 |
2003年 | 49篇 |
2002年 | 54篇 |
2001年 | 8篇 |
2000年 | 8篇 |
1999年 | 10篇 |
1998年 | 17篇 |
1997年 | 10篇 |
1996年 | 4篇 |
1995年 | 4篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 8篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 9篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1979年 | 6篇 |
1978年 | 2篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 3篇 |
1968年 | 5篇 |
1967年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有1333条查询结果,搜索用时 15 毫秒
101.
Gabriella Horvath Boglarka Racz Dora Reglodi Krisztina Kovacs Peter Kiss Ferenc Gallyas Jr Zita Bognar Aliz Szabo Tamas Magyarlaki Eszter Laszlo Andrea Lubics Andrea Tamas Gabor Toth Peter Szakaly 《Journal of molecular neuroscience : MN》2010,42(3):411-418
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with highly efficient cytoprotective actions. Its neuroprotective effects are well-known, but PACAP is able to exert similar actions in non-neuronal cells. Recently, we have shown that PACAP prolongs renal ischemic time, decreases mortality, and attenuates tubular degeneration in a rat model of renal ischemia/reperfusion, but the mechanism of renoprotection is not yet known. Therefore, the aim of the present study was to obtain further insight into the renoprotective effects of PACAP by examining its direct effects of PACAP on mitochondrial permeability transition in vitro and on the expression of the anti-apoptotic Bcl-2 and cytokines/chemokines in kidney tissues following 45 and 60 min renal ischemia and reperfusion in vivo. We found that PACAP did not have any direct effect on mitochondrial permeability transition. Cytokine array revealed that the expression of a few cytokines/chemokines was strongly increased after ischemia/reperfusion, which was ameliorated by PACAP treatment. Furthermore, in rats subjected to renal ischemia, PACAP treatment counteracted the ischemia/reperfusion-induced decrease of the anti-apoptotic Bcl-2, both after 45 and 60 min ischemia, as analyzed by Western blot. In summary, we showed that PACAP could attenuate tissue injury involving both anti-inflammatory and anti-apoptotic effects, but not directly acting on mitochondrial permeability transition. 相似文献
102.
R. Brubel A. Boronkai D. Reglodi B. Racz J. Nemeth P. Kiss A. Lubics G. Toth G. Horvath T. Varga D. Szogyi E. Fonagy J. Farkas A. Barakonyi Sz. Bellyei L. Szereday M. Koppan A. Tamas 《Journal of molecular neuroscience : MN》2010,42(3):450-458
Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide with survival-promoting actions, has been observed in endocrine organs and is thought to play a role in reproductive functions, including pregnancy. PACAP occurs in two forms, 27 and 38 amino acid residues, with PACAP38 being the predominant form in human tissues. In the present study, we determined the concentrations of PACAP38 and PACAP27 in first-trimester and full-term human placentas using radioimmunoassay. We found high levels of PACAP38 and lower levels of PACAP27 in different parts of the full-term human placenta. PACAP38 content increased in the placenta during pregnancy, both on the maternal side and on the fetal side. The effects of PACAP on the survival of JAR human choriocarcinoma cells were investigated using flow cytometry and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) cell viability assay in cells exposed to the widely used chemotherapeutic agent methotrexate (MTX). It was found that PACAP neither influenced the survival of JAR cytotrophoblast cells nor affected cellular response to the death-inducing effect of the chemotherapeutic agent MTX. The present observations further support the significance of PACAP in the human placenta. The observation that PACAP did not influence the effects of MTX may have future clinical importance, showing that PACAP does not decrease the effects of certain chemotherapeutic agents. 相似文献
103.
104.
Slamon D Eiermann W Robert N Pienkowski T Martin M Press M Mackey J Glaspy J Chan A Pawlicki M Pinter T Valero V Liu MC Sauter G von Minckwitz G Visco F Bee V Buyse M Bendahmane B Tabah-Fisch I Lindsay MA Riva A Crown J;Breast Cancer International Research Group 《The New England journal of medicine》2011,365(14):1273-1283
105.
106.
107.
108.
109.
Our present view that the mood disorders involve dysfunction of monoaminergic system is a result of important clinical and preclinical observations over the past 40 years. The therapeutic efficacy of drugs such as the tricyclic antidepressants (TCAs), monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs) and lately of SNRIs (serotonin and norepinephrine reuptake inhibitors) helped to shape our view that mood regulation involves the monoaminergic systems in some way. It is thus little surprising when the neuropeptide, galanin, is discovered to coexist with norepinephrine (NE) in locus coeruleus (LC) neurons and with serotonin (5-HT) in the dorsal raphe nucleus (DRN) neurons, a link between galanin mediated signaling and mood regulation is sought. Galanin receptors are expressed in brain structures that are involved in the regulation of mood such as frontal cortex, amygdala, hypothalamus, LC, DRN and hippocampus. It is almost an accident of research fate that the potent effects of galanin on cognitive performance and seizure threshold have led galanin research to focus on the hippocampus where the neuropeptide is present in cholinergic and noradrenergic afferents and where the receptor density is much lower than in the monoaminergic nuclei. Hopefully it is not too late to report on the recent inroads into the roles of galanin and of galanin receptor subtypes 2 and 3 (GalR2 and GalR3) in mood regulation in animal models as well as in human patients with major depression. A body of existing data suggests that GalR2 signaling leads to antidepressant-like, anticonvulsant and neurogenesis-promoting effects, a spectrum of activities that are commonly associated with efficacious antidepressants. Similarly, GalR3 antagonists exhibit anxiolytic and antidepressant-like activity, another clinically useful combination for the treatment of mood disorders. Since both GalR2 and GalR3 are G-protein coupled receptors (GPCRs), a favorite target class for drug development, we believe that the pace of developing galaninergic antidepressants will increase significantly from now on. 相似文献
110.